A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancerQingyuan Zhang, Huiping Li, Zhongsheng Tong et al.|BMC Medicine|2022Cited by 37